CMS issues extension to non-ACA compliant plans

New guidance on insurance standards were issued Feb. 23 by CMS that give another extension to health plans that are non-compliant with the Affordable Care Act (ACA), the fourth extension of its kind.

The new policy says that CMS will allow states to extend transitional plans, or plans that were grandfathered into the program and are exempt from most of the ACA reform provisions. It applies to plans that begin on or before Oct. 1, 2018, and do not extend past Dec. 31, 2018.

Additionally, the policy ensures that states will have control over permitting these policies to continue.

“This approach will facilitate smooth transitions from transitional coverage to ACA-compliant coverage, which requires a calendar year policy year in the individual market,” CMS said in the announcement.

Some speculate the extension could be an attempt from President Donald Trump’s administration to ensure that at least some Americans remain covered if lawmakers repeal and replace the ACA.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.